Roche Laboratories' Xenical, its much-anticipated prescription weight-reducing drug, underwent its first hearing before a Food & Drug Administration advisory committee May 14. The session was the first step toward full approval for marketing, which could could come as soon as this fall. Lowe
& Partners/SMS, New York, won the estimated $50 million to $60 million account.
Copyright May 1997, Crain Communications Inc.